Federal Officials and Scientists Respond to Purported CDC Word Ban

The alleged ban prohibits officials at the Centers for Disease Control and Prevention from using a list of seven words in agency budget documents.

Written byKatarina Zimmer
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

CDC′s Tom Harkin Global Communications Center in Atlanta, Georgia WIKIMEDIA, JAMES GATHANY At a 2018 budget meeting last Thursday (December 14), officials at the Centers for Disease Control and Prevention (CDC) were told by senior agency officials that they were prohibited from using a list of seven words or phrases in budget documents. The list included the terms “fetus,” “transgender,” “vulnerable,” “entitlement,” “diversity,” “evidence-based,” and “science-based,” according to a report by The Washington Post.

The news quickly sparked outrage among scientists, who expressed concern that the CDC’s work is being politicized. Federal officials have weighed in on the discussion, pushing back against the notion that the alleged ban is explicit.

“I want to assure you there are no banned words at CDC. We will continue to talk about all our important public health programs,” Brenda Fitzgerald, director of the CDC, tweeted on Sunday.

Fitzgerald’s tweet elicited a heated debate in some 900 comments by Twitter users, many of which ask for further explanation or demand that she tweet the prohibited words to demonstrate that they are not banned.

It is still unclear whether the alleged ban applies beyond budget documents and whether it stemmed from the CDC itself or ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies